Almirall SA (ALM.MC)

ALM.MC on Madrid SE C.A.T.S.

14.13EUR
24 Dec 2014
Price Change (% chg)

€0.13 (+0.93%)
Prev Close
€14.00
Open
€14.00
Day's High
€14.25
Day's Low
€13.92
Volume
38,300
Avg. Vol
339,959
52-wk High
€14.98
52-wk Low
€10.60

ALM.MC

Chart for ALM.MC

About

Almirall SA is a Spain-based company principally engaged in the research, development, storage and distribution of pharmaceutical products. The Company’s range of products include a variety of drugs for the treatment of diseases in such therapeutic areas as asthma, chronic obstructive pulmonary disease (COPD), gastrointestinal... (more)

Overall

Beta: 0.52
Market Cap (Mil.): €2,443.80
Shares Outstanding (Mil.): 172.95
Dividend: 0.15
Yield (%): 1.08

Financials

  ALM.MC Industry Sector
P/E (TTM): -- 38.36 38.84
EPS (TTM): -0.07 -- --
ROI: -0.98 18.99 18.26
ROE: -1.35 19.74 19.12
Search Stocks

Spain's Almirall gains on report of Actavis interest

Dec 19 - Shares in Spanish drugmaker Almirall jumped 9 percent on Friday after a Bloomberg report of potential takeover interest from Actavis.

19 Dec 2014

BRIEF-Shares in Spain's Almirall up 13 percent on takeover talk

* Rise around 13 percent at 1615 GMT after Bloomberg report of potential takeover interest by Actavis

19 Dec 2014

BRIEF-Almirall's treatment approved by European Commission

* Says gets authorization from European Commission to sell drug combination of aclidinium + formoterol in European Union (EU)

24 Nov 2014

BRIEF-Almirall sees FY net sales post deal low teen percent growth

* Sees FY total revenue post deal low single digit growth

10 Nov 2014

BRIEF-Almirall 9-month net profit rises by 96.8 pct to 42.9 mln euros

* Reports 9-month revenue up by 7 percent to 654.1 million euros

10 Nov 2014

BRIEF-AstraZeneca completes Almirall respiratory disease deal

* Completes strategic transaction with Almirall in respiratory disease

03 Nov 2014

EU agency backs Almirall lung drug being bought by AstraZeneca

LONDON - A combination drug for chronic lung disease from Spain's Almirall, one of a number of respiratory medicines being acquired by AstraZeneca, has been recommended for approval by European regulators.

25 Sep 2014

EU agency backs Almirall lung drug being bought by AstraZeneca

LONDON, Sept 25 - A combination drug for chronic lung disease from Spain's Almirall, one of a number of respiratory medicines being acquired by AstraZeneca, has been recommended for approval by European regulators.

25 Sep 2014

Almirall says in deal with Astrazeneca over respiratory business

MADRID, July 30 - Spain's Almirall on Wednesday said it had reached a deal to transfer to Astrazeneca the rights of its respiratory franchise for an initial $875 million. (Reporting by Julien Toyer; Editing by Tracy Rucinski)

30 Jul 2014

AstraZeneca boosts lung drug business with up to $2.1 bln Almirall deal

LONDON, July 30 - AstraZeneca took a major step to build up its respiratory medicine business on Wednesday by striking a deal worth up to $2.1 billion to acquire the rights to lung drugs developed by Spain's Almirall.

30 Jul 2014

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: GlobalData
$125.00
Provider: Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks